

Bevacizumab for retinal vein occlusions

Authors: Ron A. Adelman, M.K. George, New Haven, CT, USA

Advantages:

Improvement in visual acuity and macular edema in patients with retinal vein occlusions.

Methods:

19 patients with retinal vein occlusions were included in the study. Patients received monthly injections of bevacizumab for 3 months. During follow up, additional injection was performed if edema was detected on OCT.

Effectiveness / Safety:

Significant reduction of macular edema was noted. Central macular thickness reduced from a baseline of 455 micron to 274 micron. -0.29 log MAR and -0.35 log MAR improvement in visual acuity were noted after 3rd injection and at the end of follow up respectively.

Take home message:

Intravitreal bevacizumab leads to clinically significant reduction in macular edema as well as improvement in visual acuity.